Stay up-to-date with the latest happenings in the rapidly evolving field of In Vitro Diagnostics (IVD) in China.

To ensure the quality and safety of medical services in primary healthcare institutions, China’s National Health Commission (NHC) and other relevant authorities issued a notice on 1 April 2026, outlining a three-year nationwide action.

Baxter International Inc. (NYSE:BAX), a global medtech leader, announced today it has completed its acquisition of Hillrom. Baxter paid $156.00 in cash for each outstanding share of Hillrom common stock for a purchase price of $10.5 billion (based on Hillrom share counts at closing).

Recently, Autobio's thyroid functional magnetic particle chemiluminescence series reagents obtained the EU IVDR CE certification issued by TüV SüD. This is the first series of Autobio’s products to obtain the EU IVDR CE certification.

The US Food and Drug Administration released a notice on Thursday that Meridian Biosciences' Revogene SARS-CoV-2 test is unlikely to be able to detect the Omicron variant.

Qiagen and Denovo Biopharma said on Thursday that they are collaborating to develop a blood-based companion diagnostic test to identify patients expressing a genomic biomarker who are likely to respond to Denovo's investigational DB102 treatment for diffuse large B-cell lymphoma.

Tumors are heterogeneous, which means that different parts of the same tumor can be genetically distinct. This phenomenon, known as intratumor heterogeneity, is steadily gaining in significance within the field of cancer research.

On December 8, Roche Diagnostics China (hereinafter referred to as "Roche") and SHAPHAR announced the opening of a new round of strategic cooperation.

A potentially game-changing Antigen Rapid Test (ART) technology to diagnose COVID-19 has been developed by scientists in Singapore.

Thermo Fisher Scientific said on Thursday that the US Food and Drug Administration has granted premarket approval to the company's Oncomine Dx Target Test as a companion diagnostic for Janssen Biotech's targeted lung cancer treatment amivantamab-vmjw (Rybrevant).

Dec. 8, 2021 -- Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, today announced that it has completed its acquisition of PPD, Inc. (Nasdaq: PPD), a leading global provider of clinical research services to the biopharma and biotech industry, for $17.4 billion.

UK molecular diagnostics company Genedrive said on Wednesday that its rapid molecular COVID-19 test has received CE marking.